“Dasatinib Tyrosine Kinase Inhibitor As Second and Third Line Therapy in Chronic Myeloid Leukemia: Outcome of a Nepalese Study”. 2018. Journal of Patan Academy of Health Sciences 5 (1): 47-56. https://doi.org/10.3126/jpahs.v5i1.24042.